XBIO Stock Analysis: Buy, Sell, or Hold?
XBIO - Xenetic Biosciences, Inc.
$2.66
0.13 (4.93%)
▲
5d:
+6.4%
30d:
-3.97%
90d:
-10.44%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 11, 2026
6d
Get Alerted When XBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: XBIO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: XBIO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: XBIO is currently trading at $2.66, which is considered slightly low relative to its 30-day fair value range of $2.61 to $2.89.
Technical Outlook: Technically, XBIO is in a downtrend. Immediate support is located at $2.37, while resistance sits at $2.99. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: XBIO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $40.00 (+1403.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, XBIO is in a downtrend. Immediate support is located at $2.37, while resistance sits at $2.99. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: XBIO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $40.00 (+1403.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.61 -
$2.89
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.9%)
- BULLISH: Trading 1403.8% below Wall St target ($40.00)
Trading Range Analysis
30-Day Trading Range
$2.61 -
$2.89
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.37
Resistance Level
$2.99
Current Trend
Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.82
Wall Street Target
$40.00
(+1403.8%)
Revenue Growth (YoY)
36.0%
Profit Margin
-70.0%
Share & Embed Analysis
Last updated: August 03, 2026 11:53 PM ET
Data refreshes hourly during market hours. Next update: 12:53 AM
Data refreshes hourly during market hours. Next update: 12:53 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XBIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$386 | 43 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 54 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
